Markets

The FDA Accepts And Grants Priority Review to AstraZeneca’s Supplemental Biologics License Application For Imfinzi (Durvalumab) Combined With Enfortumab Vedotin For Muscle-invasive Bladder Cancer Who Are Ineligible For Or Have Declined Cisplatin-based Chemotherapy

Sep 25, 2026 · 06:00 AM ET· updated 1h ago

https://www.astrazeneca.com/media-centre/press-releases/2026/perioperative-imfinzi-plus-neoadjuvant-enfortumab-vedotin-granted-priority-review-in-the-us-for-patients-with-muscle-invasive-bladder-cancer.html

Why It Matters

The FDA is fast-tracking review of AstraZeneca's new bladder cancer medicine combo. This suggests the treatment shows promise, so watch for approval news ahead.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.

Tickers in Play

AZN165.12

+0.56 (+0.34%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.